Gleevec, a cancer drug first approved for sale in 2001, has dramatically changed the lives of people with chronic myeloid leukemia. This form of cancer was once regarded as very difficult to combat, but survival rates of patients who respond to Gleevec now resemble that of the population at large.
How federally funded research has helped create life-changing medicines
